CDKN2AIP

Across TCGA pan-cancer cohorts, CDKN2AIP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDKN2AIP data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDKN2AIP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDKN2AIP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CDKN2AIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.763	0.442	.003	30	view →
PDAC	DFS	Median	III,IV	0.982	0.403	.002	27	view →
LUAD	OS	Tertile	All	0.944	0.746	.006	6	view →
LSCC	OS	Median	All	1.000	0.939	.015	3	view →
GBM	OS	Tertile	All	0.481	0.220	.029	2	view →
HNSC	OS	Tertile	II,III,IV	0.860	0.634	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDKN2AIP–CCRCC (DFS)

Open the CCRCC breakdown →